Johnson & Johnson (JNJ -2.7%) announces that its COVID-19 vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in a challenge study in Syrian golden hamsters. The results were just published in Nature Medicine.
Results showed robust protection, as indicated by vaccine-elicited binding and neutralizing antibody responses, against severe clinical disease after high-dose SARS-CoV-2 infection, the first such report on this stage of the disease, according to the company.
Viral loads in the lung decreased from day 2 to day 7 while inflammatory markers continue to escalate, correlated with continue weight loss.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.